

**Curriculum Vitae**  
**James A. Solomon, MD, PhD**

Director, Ameriderm Research  
Professor Dermatology, University Central Florida, College of Medicine  
Clinical Professor, Florida State University College of Medicine  
Adjunct Clinical Professor Dermatology, Kansas City University of Medicine & Biosciences  
Assistant Clinical Professor, University Illinois, College of Medicine

**Diplomate of American Board of Dermatology**, December 1983  
**State of Florida**, ME 91126, 8/03/2004 – current

**Office:**

**Leavitt Medical Associates of FL, Inc d/b/a Ameriderm Research**

725 West Granada Blvd, Suite 44  
Ormond Beach, FL 32174  
Office: (386) 523 0768 Fax: (386) 366 9212  
Email: [drjsolomon@ameridermresearch.com](mailto:drjsolomon@ameridermresearch.com)  
[drjsolomon@knights.ucf.edu](mailto:drjsolomon@knights.ucf.edu)  
[avibenzv@illinois.edu](mailto:avibenzv@illinois.edu)

**Education:**

*Academic*

June 1976 - June 1979

SUNY at Buffalo School of Medicine  
3435 Main Street, Buffalo, NY

**MD**

June 1972 - May 1976

SUNY Upstate Medical Center  
766 Irving Avenue, Syracuse, NY

**PhD – Immunology**

September 1968 - May 1972

Johns Hopkins University  
3400 N Charles Street, Baltimore, MD

**BA: Natural Sciences**

*Fellowships*

September 1978 - June 1979

Massachusetts General Hospital, Boston, MA

**Research Fellow in Medicine**

January 1977 - June 1977

Roswell Park Memorial Institute  
Louis Sklarow Memorial, Buffalo, NY

**Dermatology/Oncology Research Fellowship**

July 1972 - June 1976

SUNY, Upstate Medical, Syracuse, NY

**National Institutes of Health Training Fellowship**

*Residency*

July 1980 - June 1983

University Hospital, Boston, MA

**Dermatology**

*Internship*

November 1979 - June 1980

Boston City Hospital, Boston, MA

**Pathology**

July 1979 - October 1979

New England Medical Center Hospital, Boston, MA

**Pediatrics**

**Work History**

January 2009 - Present

**Leavitt Medical Associates of FL, Inc. d/b/a)**

Ameriderm Research, Ormond Beach, FL

**Director**

January 2006 - 2008

**Leavitt Medical Associates of FL, Inc. d/b/a**

Research Division, Advanced Dermatology Cosmetic Surgery, Ormond Beach, FL

**Director**

August 2004 - Present

**Leavitt Medical Associates of FL, Inc. d/b/a**

Advanced Dermatology and Cosmetic Surgery, Ormond Beach, FL

**Dermatologist**

August 2001 - July 2004

Decatur Memorial Hospital

2300 N Edwards, Decatur, IL

**Dermatologist**

January - July 200

Host, "Perfect Skin", Talk radio Sunday 11am WNNZ 640 am.

March 1990 - July 2001

Aesthetique Skin International/James A Solomon MD PhD PC

171 Dwight Road, Longmeadow, MA 01106

**Owner**

February, 1986 - February, 1990

Medical West Community Health Plan, Chicopee, MA

**Chief Dermatology**

February 1985 - January 1986

Medical West Community Health Plan, Chicopee, MA

**Staff Dermatologist**

July 1983 - February 1985

Boston University School of Medicine

Department of Dermatology, Boston, MA

**Assistant Research Professor**

## **Teaching and Staff**

### **Appointments:**

**2018-2023**

Adjunct Professor Dermatology, Kansas City University of Medicine & Biosciences

**2017- present**

Faculty & Primary Advisor Residents Research Activities. Kansas City University of Medicine & Biosciences- GME Consortium. Advanced Dermatology & Cosmetic Surgery (ADCS) Orlando  
Dermatology Residency

**2017- present**

Clinical Professor Dermatology, Florida State University, College of Medicine

**2016 - present**

Professor of Dermatology, University of Central Florida, College of Medicine, Department of Medical Education

**2007-2015**

Associate Professor of Dermatology, University of Central Florida, College of Medicine, Department of Medical Education

**2001-present**

Assistant Clinical Professor, Dermatology University Illinois Urbana-Champaign, College of Medicine

**2004-2008**

Teaching and Courtesy Staff, Dermatology Department, Halifax Hospital, Daytona Beach, FL

**August 2001 — 2004**

Consulting Staff, Decatur Memorial Hospital, Decatur IL

**2001— 2004**

Assistant Clinical Professor, Dermatology, Southern Illinois University, School of Medicine, Springfield, IL

**1987 - 2001**

Assistant Clinical Professor of Dermatology, Tufts University School of Medicine, Boston IL

**1985 - August 2001**

Associate Staff, Dermatology, Baystate Medical Center, Springfield, MA

**1985 - 1991**

Courtesy Staff, Dermatology, Holyoke Hospital, Holyoke, MA

**February 1985 - August 2001**

Courtesy Staff, Dermatology, Mercy Hospital, Springfield, MA

**February 1985 - 1986**

Adjunct Assistant Professor, Department Microbiology, Boston University Medical School, Boston, MA

**July, 1983 - February, 1985**

Consultant in Dermatology, Lemuel Shattuck Hospital, Boston, MA

**July, 1983 - February, 1985**

Assistant Visiting Physician in Dermatology, Boston City Hospital, Boston, MA

**July, 1983 - February, 1985**

Assistant Visiting Physician in Dermatology, University Hospital, Boston, MA

**July, 1983 - February, 1985**

Assistant Research Professor of Dermatology, Boston University School of Medicine, Boston, MA

**July, 1981 - June, 1983**

Research Instructor, Boston University School of Medicine, Boston, MA

## **Certifications**

8/7/18 valid until 8/7/20

America AED/CPR Association Certificate Healthcare Provider CPR Course

Completion Date 23-May-2018 Expiration Date 23-May-2019

CITI Program course: **Good Clinical Practice Course for Clinical Trials Involving Drugs (ICH focus)** (Curriculum Group) **GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus)** (Course Learner Group) 1 - **Basic Course** Under requirements set by: **Kansas City University of Medicine and Biosciences**

Completion Date 21-May-2018 Expiration Date 20-May-2020

CITI Program course: **Human Research** (Curriculum Group) **Biomedical Investigators** (Course Learner Group) 3 - **Refresher Course** (Stage). Under requirements set by: **Kansas City University of Medicine and Biosciences**

Completion Date 21-May-2018 Expiration Date 20-May-2021

CITI Program course: **Human Research** (Curriculum Group) Group 1. **Biomedical Research Investigators and Key Personnel** (Course Learner Group) 4 - **Refresher Course** (Stage) Under requirements set by: **University of Central Florida**

Completion Date: 21-May-2018 • Expiration Date: 20-May-2021

CITI Human Research: • Curriculum Group: **Human Research** • Course Learner Group: Group 1. **Biomedical Research Investigators and Key Personnel** • Stage: Stage 4 - **Refresher Course** • Record ID: 26079449 • Institution Affiliation: **University of Central Florida** (ID: 405)

Completion Date: 21-May-2018 • Expiration Date: 20-May-2020

CITI Program course: • (ID: 443) • Curriculum Group: **Human Research** • Course Learner Group: Group 1. **BIOMEDICAL RESEARCH** • Stage: Stage 3 - **Refresher Course** • Record ID: 22221517 • Institution Affiliation: **Western IRB**

Completion Date 21-May-2018 Expiration Date 20-May-2021

CITI Program course: **Biomedical Responsible Conduct of Research** (Curriculum Group) **Biomedical Responsible Conduct of Research** (Course Learner Group) 2 - **RCR Refresher** (Stage) Under requirements set by: **Kansas City University of Medicine and Biosciences**

Completion Date 21-May-2018 Expiration Date 20-May-2020

CITI Human Research: **Human Research** (Curriculum Group) Group 1. **BIOMEDICAL RESEARCH** (Course Learner Group) 3 - **Refresher Course** (Stage) **Western IRB**

Completion Date: 21-May-2018 • Expiration Date: 21-May-2019

CITI Human Research: (ID: 829) • Curriculum Group: **CITI Health Information Privacy and Security (HIPS)** • Course Learner Group: **CITI Health Information Privacy and Security (HIPS) for Clinicians** • Stage: Stage 1 - **Basic Course** • Record ID: 23461056 • Institution Affiliation: **Kansas City University of Medicine and Biosciences**

Completion Date 20-Mar-2018 Expiration Date 19-Mar-2020

CITI Program course: **CITI Health Information Privacy and Security (HIPS)** (Curriculum Group) **CITI Health Information Privacy and Security (HIPS) for Clinical Investigators** (Course Learner Group) 1 - **Basic Course** (Stage) Under requirements set by: **Kansas City University of Medicine and Biosciences**

Completion Date: 07/09/2017 • Expiration Date: 07/28/2021

CITI Human Research • **Conflict of Interest mini-course** (Curriculum Group) **Conflict of Interest** (Course Learner Group) 1 (Stage) **Western IRB**

Completion Date: 09-Jul-2017 • Expiration Date: 09-Jul-2019

CITI Human Research: Curriculum Group: **Additional Groups in the Course for The Protection of Human**

**Subjects • Course Learner Group: Investigators (Biomedical) • Stage: Stage 1 - Basic Course •**  
Institutional Sponsor: **Schulman Associates IRB** Record ID: 22221516 •  
6/17/16 valid until 6/17/18

American AED/CPR Association Certificate Healthcare Provider CPR Course  
6/21/2016

**GCP Investigator Site Personnel Training**, Version 1.0, Meeting TransCelerate BioPharma  
Completion Date: 05/06/2015 • Expiration Date: 05/04/2020

**CITI Biomedical Research - Basic/Refresher Course**; Institutional Sponsor **Liberty IRB**  
Completion Date: 05/06/2015 • Expiration Date: 05/04/2020

**CITI Responsible Conduct of Research Course**. Institutional Sponsor **Liberty IRB**  
Completion Date: 05/06/2015 • Expiration Date: 05/04/2020

**CITI Biomedical Research: Good Clinical Practice Course Course Learner Group:** CITI Good Clinical Practice Course • **Stage:** Stage 1 - **Basic Course**. Institutional Sponsor **Liberty IRB**  
Completion Date: 05/06/2015 • Expiration Date: 05/05/2019

**CITI Biomedical Research: Conflicts of Interest Course Learner Group: Conflicts of Interest • Stage:** Stage 1 - Stage 1 Institutional Sponsor **Liberty IRB**

Completion Date: 05/06/2015 • Expiration Date: 05/04/2020

**CITI Biomedical Research: Information Privacy Security (IPS) Course Learner Group:** Researchers • **Stage:** Stage 1 - **Basic Course** Institutional Sponsor **Liberty IRB**

Completion Date: 05/06/2015 • Expiration Date: 05/05/2017

**CITI Biomedical Research: Additional Groups in the Course for The Protection of Human Subjects**  
Course Learner Group: Investigators (Biomedical) • **Stage:** Stage 2 - **Refresher Course** Institutional Sponsor **Schulman Associates IRB**

Completion Date: 05/06/2015 • Expiration Date: 05/05/2018

**CITI Human Research • Course Learner Group: Group 1. Biomedical Research Investigators and Key Personnel • Stage:** Stage 3 - **Refresher Course** Institutional Sponsor: **University of Central Florida IRB**  
May 2015

TransCelerate ICH GCP Investigator Training V1.2 29

Completion Date: 04/01/2015 • Expiration Date: 03/31/2017

**CITI Human Research: GCP Course** Institutional Sponsor: **Salus IRB**  
06/09/14

CITI ICH - Comparison Between ICH GCP E6 and U.S. FDA Regulations  
06/07/2013

CITI Course Basic/Refresher Course - Human Subjects Research Curriculum Principal Investigator and Research Staff

06/07/2013

CITI Course Good Clinical Practice Curriculum

5/31/13 valid until 5/31/15

American AED/CPR Association Certificate Healthcare Provider CPR Course  
08/01/12

CITI Course Biomed Refresher 2 – SBR Methodologies in Biomedical Research  
12/26/11

CITI Course for the Protection of Human Subjects Curriculum Investigators (Biomedical) (IIRB)  
8/22/2011

NIH Office of Extramural Research, Web-based training course “Protecting Human Research Participants” certificate # 729868

8/29/2010 valid until 8/29/2012

American AED/CPR Association Certificate Healthcare Provider CPR Course  
11/24/09

CV: James A Solomon MD PhD

CITI Course for the Protection of Human Subjects Curriculum Investigators (Biomedical) (IIRB)  
11/24/09  
CITI Course Health Information Privacy and Security for Clinical Investigators (IIRB)  
11/23/09  
CITI Good Clinical Practice Course (IIRB)  
11/23/09  
CITI Refresher Course- Human Subjects Research Curriculum (RCRC IRB)  
11/23/09  
CITI GCP Basic Course (RCRC IRB)  
7/30/2008 valid until 7/30/2010  
American AED/CPR Association Certificate Healthcare Provider CPR Course  
02/17/08  
CITI Good Clinical Practice Curriculum program (RCRC IRB)  
02/16/08  
CITI Basic Course – Human Subjects Research Curriculum (RCRC IRB)  
2004-2005  
Advanced Dermatology & Cosmetic Surgery, Moh's Microscopic Controlled Surgery Training  
1997  
Certificate, Clinical Use of the CO2 Laser in Cosmetic Skin Resurfacing, Luxar Corporation  
1980  
Diplomat, National Board of Medical Examiners

**Honors, Honorary Societies:**

2011  
American Academy of Dermatology, AAD Leadership Circle  
For Volunteerism, Gold Level  
Jan 2007  
American Academy of Dermatology, AAD Leadership Circle  
For Volunteerism, Bronze Level  
May 2007  
President's Volunteer Service Award, USA Freedom Corps  
1990 – 2004  
Physician Recognition Award, American Medical Association  
1972  
With Honors, Johns Hopkins University  
1971  
Alpha Epsilon Delta, Johns Hopkins University,

**Professional Societies:**

American Hair Research Society– 2017 present  
Acne Core Outcome Network (ACORN) 2015- present  
Group for Research & Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Member, 2013- present  
International Dermatology Outcome Measures (IDEOM) Member–2013-present  
International Dermatoepidemiology Association (IDEA), member 2010-present  
American DermatoEpidemiology Network (ADEN), Member 2009- present.  
Central Florida Society of Dermatology 2009-present  
American Federation for Medical Research, Member, 2006- present  
American Federation for Clinical Research, Member, 1982 – 1985  
Society for Investigative Dermatology, Member, 2006- present  
Society for Investigative Dermatology, Member, 1983 – 2000  
Society for Investigative Dermatology, Resident— Fellow Member, 1982 -1983

Association of Clinical Research Professionals, Member, 2006 – present  
American Society for Laser Medicine and Surgery, Fellow 2002- present  
National Psoriasis Foundation, Member, 1988 - present  
American Academy of Dermatology, Fellow, 1983 - Present  
Massachusetts Medical Society, Member, 1983-Present  
    Massachusetts Medical Society, Resident Member, 1981 — 1983  
Royal Society of Medicine (United Kingdom), Member 2011- 2013  
Society of Clinical Research Associates, Member, 2006-2008  
American Society of Cosmetic Dermatology and Aesthetic Surgery-member 2002- 2010  
Illinois State Medical Society; Member 2001-2004  
Macon County Medical Society; Member 2001 —2004  
International Society for Hair Replacement Surgery, Member, 1998- 2001  
Royal Society of Medicine (United Kingdom), Member-1998 — 2001  
Society for Pediatric Dermatology, 1991 - 2001  
American Contact Dermatitis Society, 1990 - 2001  
Member, Quinsigamond Dermatologic Society (University of Massachusetts Medical School, Department  
Dermatology), 1990-2001  
American Dermatologic Society for Allergy and Immunology, Member,  
1985 - 2004  
American Medical Association, Member, 1983 –2001  
    American Medical Association, Resident Member, 1979—1983  
    American Medical Association, Student Member, 1977—1979  
American Association for the Advancement of Science, 1983 — 1985  
Massachusetts Academy of Dermatology, 1983 - 1985  
Hubert H. Humphrey Cancer Center, Member, 1981 —1985

**National, State, and Local  
Committee Appointments:**

Member of Patient Advocate Task Force, American Academy Dermatology 2018-2020  
Consultant, Mayne Pharma, 2018- present  
Consultant Aspyrian Therapeutics Inc, 2018-present  
Reviewer, New England Journal of Medicine 2018- present  
Reviewer, American Journal of Clinical Dermatology 2018 present  
Reviewer, European Journal Pharmacology 2018-present  
Reviewer, Springer Current Dermatology Reports 2018- present  
Reviewer, Case Reports in Dermatologic Medicine 2017- present  
Consultant, Sun Pharmaceutical, 2017- present  
Consultant, Eli Lilly 2017 – present  
Reviewer, British Journal Dermatology 2016-present  
Reviewer, Flagship: Medical Scholarly Proceedings UCF COM, 2016- present  
Member of Kansas City University of Medicine and Biosciences Scholarly Activity & Faculty Development  
Committee Meeting Oct 2016- present  
ACORN communications section leader 2016- present  
Reviewer, Journal Dermatological Treatment, 2013- present  
Reviewer, JAMA –Dermatology 2013- present  
Scientific Advisory Board, National Alopecia Areata Foundation, 2013- present  
American Dermatoepidemiology Network (ADEN) / Epidemiology Expert Resource Group, webmaster  
2011- present  
Alopecia Areata Clinical Research Task Force, National Alopecia Areata Foundation, 2010- present  
Epidemiology Expert Resource Group (Epi-ERG) - American Academy of Dermatology 2010- present  
Reviewer, Journal American Academy of Dermatology, 2009 – Present

Scientific Advisory Board, Samumed, 2016  
Member of the Clinical Guidelines Committee of the AAD. 2015-2017  
Member, Scientific Advisory Board of Basal Cell Carcinoma Nevus Syndrome Life Support Network 2014-2016  
Erivedge Dermatologist Advisory Board, Genentech, 2013.  
Scientific Advisory Board, Xenoport, 2013  
Assistant Editor, Journal American Academy of Dermatology, 2013-2018  
Hedgehog Inhibitor & Advanced Basal Cell Carcinoma Advisory Board, Eli Lilly, 2012  
American Academy of Dermatology, Epidemiology Expert Resource Group (Epi-ERG), & American Dermatoepidemiology Network Cooperative Effort, Chair, pSOAR (psoriasis Outcomes Assessments Review), 2012-2014  
Epi-ERG/ ADEN, subcommittee to establish Dermato-epidemiology Clinical Trials Resource Cooperative, Chair– 2011- 2014  
Co-editor, Cutaneous Oncology Today, 2011 to 2013  
Advanced Basal Cell Carcinoma Regional Advisory Board, Genentech, 2010  
S-5 Curriculum Dermatology Section Coordinator, University of Central Florida, College of Medicine, 2008-2010  
Subcommittee S-1 Curriculum Development for Hematology Oncology, University of Central Florida, College of Medicine 2008- 2009  
Subcommittee S-6 Curriculum Development for Muscular Skeletal (Cutaneous) Systems, University of Central Florida College of Medicine, 2008-2009  
American Society for Laser Medicine and Surgery, Constitution and Bylaws Committee, 2007-2008  
Graduate Medical Education Committee, Halifax Hospital, Member 2007-2008  
Curriculum Committee, University of Central Florida, College of Medicine, 2007-2008  
American Academy of Dermatology, EPA/NIEHS/NIOSH Liaison Task Force, Member 2003-2007  
Illinois State Medical Society, Governmental Affairs Council: Member, 2002 — 2004  
Massachusetts Medical Society: Delegate, 1999-2002  
Hampden District Medical Society: Executive Board, 1999 —2002  
Contact Dermatitis Committee of American Academy of Dermatology, January 1994-March 1998.

### **Community Service:**

Jewish Federation of Volusia & Flagler Counties, Florida, Board, member, 2005 – Present  
Co-chairman, Maimonides Medical Society, Jewish Federation of Volusia & Flagler Counties, FL 2004 – Present  
Vignette Judge, 2008 Annual Research Symposium, University of Illinois College of Medicine at Urbana at Urbana Champaign, April 2008  
Member, Economic Prosperity Committee, Ormond Beach Chamber of Commerce, 2006 - 2016  
Member, Education Committee, Ormond Beach Chamber of Commerce, 2006 - 2016  
Port Orange/South Daytona Chamber of Commerce & Economic & Government Affairs Committee  
Subcommittee Chair: Health and Medical Issues. 2005-2012  
Co-chairman, Israeli Bond Drive, Champaign, IL 2002— 2004  
Community Relations Committee, Springfield Jewish Federation, 2000-2002  
Community Relations Committee, Springfield Jewish Federation, 1995  
Lubavitcher Yeshiva Academy, Board Member, Long Range Planning Committee Member, 2000— 2001  
Beth Israel Synagogue, Board Member, Director of Membership - 1995-1996  
Member, Young Leadership Development Program, Springfield Jewish Federation - 1990

### **Medical/Legal and Business Consulting:**

Consultant for Vista Society of Industry Leaders 2006- present

CV: James A Solomon MD PhD

Consultant for MedaCorp 2006- present  
Consultant for Network of Experts 2005- present  
Consultant for Network of Advisors, Clinical Advisors, LLC 2004 – Present  
Consultant for J. Reckner Associates, Inc. 2004 – Present  
Consultant for Doctor Directory 2004-present  
Gerson Lehrman Group, Councils of Advisors, 2001- present  
Expert Witness in areas of routine & cosmetic dermatology, hypersensitivity, immunology, and connective tissue diseases, as well as Product Liability Merit Analysis for various law firms in Massachusetts, Michigan, New York, Pennsylvania, South Carolina 1990— present  
Independent Medical Examiner, Department of Industrial Accidents, Commonwealth of Massachusetts, August 1995—2001  
Physician Member Medical Malpractice Tribunal, Commonwealth of Massachusetts, 1994—2001  
Product Liability Merit Analysis, *Sedwick, Detert, Moran, & Arnold*, NY, NY, June 1994 - 2001  
Merit Analysis Malpractice & Product Liability, Central & Western Mass Lawyers, March 1990 —2001  
Trial expert witness in areas of dermatology, hypersensitivity, immunology, and connective tissue disease, *Gary .Lenehan, Esq*, Manchester, NH, 1988-89.

#### **Grant Awards:**

Beg S, Solomon JA, Kolpashchikov D, Ramshaw B, Stancescu M, Updyke KM, Lewis S, Domozych R, Stines M. Identifying the genetic sequence and source of the DNA antigenic component of the anti-DNA immune complexes in systemic lupus erythematosus (SLE) in order to establish the role of exogenous antigens evoking molecular mimicry response in human SLE disease pathogenesis. University of Central Florida College of Medicine Study Pilot Laboratory Study Internal Grant 2014-2015.

#### **Clinical Trials:**

- \*A Multi-Center, Randomized, Double-Blind, XXX- and XXX Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of XXX in Subjects with Moderate-to-Severe Plaque Psoriasis - 2018
- \*A Phase 3 Randomized, XXX-Controlled, XXX-Blind Study to Evaluate XXX in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis - 2018
- \* A Phase 3, Multicenter, Randomized, xxx-Blind, xxx-And Active xxx-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety xxx in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis - 2018
- \* A Phase 3, Multicenter, xxx-label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of xxx in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis - 2018
- \* A Multicenter, Randomized, xxx-Blind, xxx-Controlled, Parallel-Group Study to Evaluate the Efficacy and safety of xxx in Adult Subjects with Moderate To Severe Chronic Plaque Psoriasis - 2018
- \* A Randomized, xxx-Blind, xxx-Controlled, Efficacy Study of the xxx Receptor Antagonist xxx in Patients with Atopic Dermatitis - 2018

- \* A Randomized, xxx-Blind, Multicenter Study Assessing Short (16 weeks) and Long-Term Efficacy (up to 1 year), Safety, and Tolerability of Sub-Cutaneous xxx in Subjects of Body Weight xx kg or xx with Moderate to Severe Chronic Plaque-Type Psoriasis - 2018
- \* A Phase Ib, xxx-Blind, Randomized, xxx-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeated Doses of xxx - 2018
- \* A Randomized, xxx-Blind, xxx-Controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics of xxx in Subjects with Moderate to Severe Atopic Dermatitis - 2018
- \*Phase 3 A Multicenter, xxx label study to assess the safety and efficacy of xxx for maintenance in Moderate to severe plaque type psoriasis - 2017
- \*Phase 3 Randomized, Double-Blind, xxx-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of xxx versus xxx in Subjects 12 years of age or older with Cutaneous Common Warts - 2017
- \*Phase 3 A Randomized, Multicenter, Double-blind, xxx-controlled Study to Evaluate the Safety and Efficacy of xxx --% Topical xxx Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea - 2017
- \*Phase 3 Randomized, Double-Blind, xxx-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of xxx for 12 Weeks in the Treatment of Moderate-To-Severe Acne Vulgaris - 2017
- \*Phase 2 Randomized, Double-Blind Dose-Ranging Study of xxx Cream in Subjects With Vitiligo - 2017
- \*Phase 2 Randomized, Dose-Ranging, Vehicle-Controlled and xxx xx% Cream-Controlled Study to Evaluate the Safety and Efficacy of xxx Cream Applied Topically to Adults With Atopic Dermatitis - 2017
- \*Phase 3 Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of xxx for 40 weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea. - 2017
- \*Phase 3 Double-Blind, xxx-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of xxx xxx X% in Adult Subjects with Actinic Keratosis on the Face of Scalp - 2017
- \*Phase 3 Efficacy and Safety of xxx in Field Treatment of Actinic Keratosis on Balding Scalp including 12-month follow-up 2016
- \*A Phase 3 Multi-Center, Randomized, Double-Blinded, xxx-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of xxx and xxx Once Daily in the Treatment of Acne Vulgaris 2016
- \*A Phase 3 Multi-Center, xxx Label Study Evaluating the Long Term Safety of xxx Once Daily in the Treatment of Acne Vulgaris 2016
- \*A Phase 2B Randomized, Double-Blind, xxx-Controlled, Parallel, Multicenter, Dose-Ranging, Study to Evaluate the Efficacy and Safety Profile of xxx in Subjects with Moderate to Severe Atopic Dermatitis 2016
- \*Phase 3 Xxx Versus xxx and xxx comparators in a randomized double blind for Maintenance use in Moderate to severe plaque type psoriasis – 2 (xxx) 2016 – Phase III
- \*Phase 2A Multicenter, Randomized, Double-Blind, xxx-Controlled, Phase 2A Study of xxx Tablets in Androgenetic Alopecia in Males with a xxx Arm - 2016
- \*Phase IIa A Multicenter, xxx, Double-Blind, xxx-Controlled Study to Assess The Safety And Efficacy of xxx in Treatment-Resistant Pruritus Associated with Atopic Dermatitis - 2016
- \*Phase 3 Efficacy and Safety of xxx in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up - 2016
- \*A Multicenter, Randomized, xxx-Blind Study Comparing the Efficacy and Safety of Xxx Dosing Regimens in Patients with Moderate-To-Severe Plaque Psoriasis
- SCORING Trial: Phase IIb Open-label Trial of xxx in Subjects with Basal Cell Carcinoma Nevus Syndrome, 2015
- \*Phase 3 A Multi-Center, Randomized, xxx-Blind, Parallel-Group, xxx Controlled Study To Compare The Efficacy and Safety of xxx Versus xxx In Subjects With Acne Vulgaris 2016

- \*A Phase 3, Multicenter, Randomized, xxx-Blind, Paralled-Group, Study Followed By a Dose-Blind Period and Open-Label Follow-Up To Evaluate the Efficacy and Safety of xxx In Subjects With Moderate to Severe Chronic Plaque Psoriasis-2015
- \*A Phase II, Randomized, Double-Blind, xxx-Controlled Study to Evaluate The Safety and Efficacy of xxx In Patients With Persistent Moderate To Severe Atopic Dermatitis That Is Inadequately Controlled By Topical Corticosteroids 2015
- \*Phase II. A Randomized, XXX-Blinded, XXX-Controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of XXX Different XXX Regimens in Patients with Multiple Basal Cell Carcinomas, 2014
- \*Phase III. An XXX-Label Study of XXX in Patients with Atopic Dermatitis Who Participated in Previous XXX Clinical Trials, 2014
- \*Phase 3. A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis 2014
- \*Phase 3. A Multicenter, Open-Label Study of the Long-Term Safety of AN2728 Topical Ointment, 2% in the Treatment of Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis 2014
- \*A Phase 2, Randomized, xxx-Blind, xxx-Controlled Study to Evaluate Safety and Efficacy of xxx in Subjects with Moderate to Severe Psoriasis 2014
- \*Phase 1 and 2, Two parts of Safety and Efficacy of Escalating doses of xxx Applied Daily for Two Consecutive Days on Approximately xxx on Trunk and Extremities in Subjects with Actinic Keratosis 2014
- \*Phase I. Pharmacokinetic Evaluations of XXX following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients with Moderate-to-Severe Plaque Psoriasis, 2013
- \*Phase III. A XXX-Week, Phase 3, Randomized, XXX-Blind, XXX-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous XXX, Followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis, 2013
- \*Phase IV. Pharmacokinetics and Pharmacodynamics of XXX mcg/g ointment applied XXX daily for XXX days Under Conditions of Maximal use in Pediatric Subjects (2 to 12 years of age) with Plaque Psoriasis, 2013
- \*Phase II. A Randomized, XXX-blind, XXX-Controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of XXX in Subjects with Moderate to Severe Hidradenitis Suppurativa, 2013
- Phase I. Safety and Efficacy of Escalating Doses of XXX Formulations Applied XXX Daily for XXX Consecutive Days on Full Face or Approximately XXX on the Chest in Subjects with Actinic Keratosis, 2013
- \*Phase II-III. A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of XXX Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence, 2012
- \*Phase II. XXX Compared with Calcipotriol plus Betamethasone Dipropionate Ointment, XXX Vehicle and Ointment Vehicle in Subjects with Psoriasis Vulgaris 2012.
- \*Phase III. A Phase 3 randomized, double-blind, 12-week vehicle-controlled, parallel-group study assessing the efficacy and safety of XXX cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40-week investigator-blinded extension comparing the long-term safety of XXX cream versus azelaic acid 15 % gel. 2012.
- \*Phase I. A Phase 1, xxx-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of XXX Foam, xxx, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) with Plaque Psoriasis. 2012.
- \*Phase III. A randomized, double-blind, vehicle-controlled, multicenter, parallel-group clinical trial to assess the safety and efficacy of XXX Foam, 15% topically applied twice daily for 12 weeks in patients with papulopustular rosacea, 2012.

\*Phase III. A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of XXX in Patients with Moderate-to-Severe Plaque Psoriasis 2012.

\*Phase III. A 12-Week Multicenter, Randomized, XXX-Blind, XXX-Controlled Study Comparing the Efficacy and Safety of XXX to XXX and XXX in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period, 2012

\*Phase III. A Randomized, XXX-Blind, Parallel-Group, XXX-Controlled, Multicenter Study Comparing XXX to XXX, XXX in the Treatment of Actinic Keratosis of the Face or Balding Scalp, 2012

Phase IV. A Prospective Observational Study Of XXX Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients, 2012

\*Phase III – A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of XXX in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail Adults 2011

\*Phase II - A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of XXX Compared with Vehicle in Women with Female Pattern Hair Loss with an Additional Open-label Active Comparator (xxx 2%) Group, 2011

\*Phase II - A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of XXX Compared with Vehicle in Men with Androgenic Alopecia with an Additional Open-label Active Comparator (xxx x%) Group, - 2011

Phase II – Topical treatment of adolescent (aged 12 – 17 years) subjects with scalp psoriasis, 2010

Phase III – Topical treatment of adolescent patients (aged 12 – 17 years) with psoriasis vulgaris, 2010

Phase III- Topical treatment of adult psoriasis vulgaris on the non-scalp regions of the body, 2010

Phase II –Oral treatment, Expanded Access Study of XXX in patients with locally advanced or metastatic basal cell carcinoma, 2010

Phase II – Dose-ranging oral treatment of severe acne vulgaris with nodules, 2010

Phase II – Topical treatment for moderate to severe facial acne vulgaris, 2010

Phase III – Parallel-group treatment/withdrawal and re-treatment of 2 oral doses of XXX of moderate to severe chronic plaque psoriasis, 2010

Phase III – Open label treatment of 2 oral doses of XXX of moderate to severe chronic plaque psoriasis

Phase III – Topical treatment of psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs), 2010

Outpatient Registry – 2010 Multicenter, open registry of patients with psoriasis who are candidates for systemic therapy including biologics

Phase III – Subcutaneous Injectable Treatment of Type II Diabetes, 2009

Phase III - Subcutaneous Injectable Treatment of Type II Diabetes, 2009

Phase III - Subcutaneous Injectable Treatment of Type II Diabetes, 2009

Phase III - Subcutaneous Injectable Treatment of Type II Diabetes, 2009

Phase III - Subcutaneous Injectable Treatment of Type II Diabetes, 2009

Phase II – Topical Treatment of Atopic Dermatitis,2009

Phase II – Topical Treatment of Atopic Dermatitis, 2009

Phase II – Topical Treatment of Atopic Dermatitis 2009

Phase II - Topical Treatment of Atopic Dermatitis 2009

Phase II – Topical Treatment of Psoriasis of Intertriginous Areas 2009

Phase III- Topical treatment of pediculosis capitis, 2009

Phase III – Oral Treatment of severe recalcitrant nodular acne, 2009

Phase III - Topical Treatment of Mild to Moderate Onychomycosis, 2009

Phase III – Oral Treatment of Severe Chronic Hand Eczema, 2009

Phase III – Topical Treatment for Mild to Moderate Acne Vulgaris, 2008

Phase III – Topical Treatment for Inflammatory Rosacea 2008  
 Phase III- Topical Treatment for Atopic Dermatitis 2008  
 Phase III- Topical Treatment of Mild to Moderate Psoriasis 2008  
 Phase II – Topical Treatment of Moderate to Severe Psoriasis 2008  
 Phase II- Oral Treatment for Atopic Dermatitis 2008  
 Phase III- Topical Treatment of Actinic Keratosis,2008  
 Phase II- Topical Treatment of Actinic Keratosis 2008  
 Phase II – Oral Treatment for Advanced Basal Cell Carcinoma, 2008  
 Phase III – Topical Treatment for Actinic Keratosis, 2007  
 Phase III – Topical Treatment for Psoriasis, 2007  
 Phase III – Topical Treatment for Actinic Keratosis, 2007  
 Phase II – Oral Treatment for Cutaneous T-Cell Lymphoma, 2007  
 Phase III – Topical Treatment for Moderate to Severe Acne Vulgaris, 2007  
 Phase III – Topical Treatment for Moderate to Severe Acne Vulgaris, 2007  
 Phase II -Validation Study for Female Alopecia, 2007  
 Phase II – Topical Treatment for Moderate to Severe Psoriasis, 2007  
 Phase III – Topical Treatment for Moderate to Severe Psoriasis, 2007  
 Phase II – Oral Treatment for Herpes Zooster, 2007  
 Phase III – Topical Treatment for Pediculosis Capitis, 2007  
 Phase III \_ - Topical Treatment for Actinic Keratosis, 2007  
 Phase III- Topical Treatment for inflammatory Rosacea 2007  
 Phase III – Oral medication for treatment of Osteoarthritis 2007  
 Phase II – Topical Treatment for Actinic Keratosis, 2006  
 Phase III – Topical Treatment for Actinic Keratosis, 2006  
 Phase III – Oral Treatment for Onychomycosis, 2006  
 Phase III – Topical Treatment for Acne Vulgaris, 2006  
 Phase III – Topical Treatment for Acne Vulgaris, 2006 / 2007  
 Phase III – Topical Treatment for Impetigo, 2006/ 2007  
 Phase III – Topical Treatment for Tinea Pedis, 2006 / 2007  
 Phase III – Topical Treatment for Actinic Keratosis, 2005 / 2006  
 Subjects with Psoriasis for Inclusion in a repository and use in Genomic (from DNA and RNA), Serologic and Metabolic (from Serum) and Proteomic (from Protein) Research Studies, 2005 / 2006  
 Healthy Subjects for inclusion in a repository and use in Genomic (from DNA and RNA), Serologic and Metabolic (from Serum) and Proteomic (from Protein) Research Studies, 2005  
 Phase III - Topical Treatment for Actinic Keratosis, 2005  
 Phase II – Topical Treatment for Acne Vulgaris, 2005  
 Phase IV - Topical Gel for Acne Vulgaris, 2000  
 Phase IV - Topical gel for Acne Vulgaris, 1999  
 Medical Device Research - Assay Process for Determining Mitogen or Antigenic Response, 1983  
 Phase III- Retrospective analysis to determine common allergens and interrupted metabolic pathways in ‘treatment resistant’ dermatologic patients with atopic dermatitis, psoriasis, alopecia areata, chronic vaginitis, and urticaria 1982-1999  
 Phase III - Immunostimulation by low dose Cytoxan, 1977  
 Phase III - Cancer immunotherapy using DNCB, 1976-1983  
 Phase III - Cancer immunotherapy using Nitrogen Mustard, 1976-1983  
 Phase III - Cancer immunotherapy using purified protein derivative, 1976-1983  
 Phase III - Viral augmented melanoma antigen, RPMI, 1976-1979  
 Pre-Clinical: Animal toxicity studies, viral augmented melanoma antigen, Roswell Park Memorial Institute, (RPMI), 1976-1977

Phase I-II - Vesicular stomatitis virus augmented melanoma antigen, RPMI, 1976-1977  
Phase III - BCG as immunoaugmentation agent in conjunction with topical immunotherapy 1976

**The Clinical Trails Listed Above Were Conducted By The Following Companies:**

Allergan, Altana, Anacor, Apotex, AstraZeneca, Asubio, Barrier, Basilea, Bayer, Boehringer Ingelheim, Biocryst, Braintree, Centocor, Celtic, Chilter, Cipher, Clynsis, Concentrics, Covance, CuTech, Dermira, Dow, Eli Lilly, Encorium, Epithany, Galderma, Genentech, Genomics, GlaxoSmithKline, Glenmark, Health Decisions, HedgePath Pharmaceutical, Hill, ICON, Incyte, Inventiv, Kendle International, Leo Pharmaceuticals, Manhattan, Maruho, MAVIS, Merck, Novartis, Noven, Novum, Omnicare, ParaPro Inc, Parexel, Peplin, Pfizer, PharmaNet, Polynoma, PPD Development, PRA, Premier, Pro Trials, Quintiles, Regeneron, Research Sample Bank, Rho, Roche, Sanofi-Aventis, SciQuus, Serentis, SGS, Steifel,, Sterling Bio, Symbio, Taisho, Taro, Teva, Therapeutics, TKL research, Tolmar, Topaz, Vanda, Worldwide Clinical Trials

**Indications:**

Alopecia Areata, Pattern Alopecia, Actinic Keratosis, Advanced Basal Cell Carcinoma, Basal Cell Carcinoma Nevus Syndrome, Squamous Cell Carcinoma, Melanoma, Lymphangiosarcoma, Cutaneous T-Cell Lymphoma, Cosmetic Dermatology, Acne Scarring, Acne Vulgaris, Rosacea, Atopic Dermatitis,, Chronic Hand Eczema, Hidradenitis Suppurativa, Psoriasis, Pediculosis Capitis, Tinea Pedis, Onychomycosis, Impetigo, Herpes Zoster, Type II Diabetes, Osteoarthritis, Healthy Volunteer

**Publications:**

Abuabara K, Asgari MM, Chen SC, Dellavalle RP, Kalia S, Secrest AM, Silverberg JI, Solomon JA, Weinstock MA, Wu JJ, Chren MM, How data can deliver for dermatology, Journal of the American Academy of Dermatology, 2018 79(2), 400-402, ISSN 0190-9622, <https://doi.org/10.1016/j.jaad.2018.03.020>. (http://www.sciencedirect.com/science/article/pii/S0190962218304705)

Urso B, Updyke KM, Solomon JA. Systemic Lupus Erythematosus and the broken dental tool. Our Dermatol Online. 2018; 9(1):99-100. Submission: 30.06.2017; Acceptance: 31.08.2017 DOI: 10.7241/ourd.2018.1.32

Urso, B, Updyke KM, Domozych R, Solomon JA, Brooks I, Burton V, Dellavalle RP, MD, PhD. Acne Treatment: Analysis of Acne-Related Social Media Posts and the Impact on Patient Care." 2018 *Cutis* **102**(1): 41-43.

Egeberg A, Wu JJ, Korman N, Solomon JA, Goldblum O, Zhaov F, Mallbris L, Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3, Journal of the American Academy of Dermatology, 2018 79(1) 104-109.e8, ISSN 0190-9622, <https://doi.org/10.1016/j.jaad.2018.02.074>. (http://www.sciencedirect.com/science/article/pii/S0190962218303682)

Shih S, Dai C, Ansari A, Urso BA, Laughlin AI, Solomon JA . Advances in genetic understanding of Gorlin syndrome and emerging treatment options, Expert Opinion on Orphan Drugs, 2018 6:7, 413-423, DOI:

CV: James A Solomon MD PhD

10.1080/21678707.2018.1483233

Shih S, Urso BA, Domozych R, Updyke, Laughlin AI, Solomon JA. Chromosome 9 mutations reported absent in some patients with Basal Cell Carcinoma Nevus Syndrome J Euro Acad Dermatol & Venerol, 2018 May; 32(5):e179-e181. doi: 10.1111/jdv.14689. Epub 2017 Dec 12.

Urso B, Solomon JA. Urticaria from penicillin as the sole clue to acute onset of disabling arthritis. Our Dermatol Online. 2018;9 (1):1-2.

Kailas, Ajay; Solomon, James; Jakus, Jeanette; Rigel, Darrell; Desai, Seemal; Taylor, Susan. Physician management differs regarding skin cancer for white compared with nonwhite patients. J Am Acad Dermatol 2018 79(3) AB221

Egeberg AA, Wu JJ, Korman NN, Solomon JA, Goldblum OO, Zhai FF, Mallbris LL. : Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, -2, and -3. J Am Acad Dermatol 2018 Mar 13. pii: S0190-9622(18)30368-2. doi: 10.1016/j.jaad.2018.02.074. [Epub ahead of print]

Nergard JC, Caldwell C, Barr M, Dellavalle RP, Solomon JA. Perception of Tanning Risk Among Melanoma Patients With a History of Indoor Tanning. *Cutis*. 2018 January; 101 (1):47-50, 55

Nergard-Martin J, Collins J, Gottlieb A, Solomon JA. Patient Research Partners: Lessons Learned from OMERACT Applied to Dermatology. J Psoriasis & Psoriatic Arthritis. 2017; 2 (4)  
<https://www.psoriasis.org/content/patient-research-partners-lessons-learned-omeract-applied-dermatology>

Updyke KM, Urso B, Ali H, Brooks I, Burton V, Dellavalle RP, Solomon JA. Following Autoimmune Diseases Through Patient Interactive Diaries: Continuous Quality Improvement. Practical Dermatology 2017; 14 (12) 48-54.

Caldwell CC, Saikaly SK, Dellavalle RP, Solomon JA. Prevalence of pediatric Alopecia Areata among 572,617 dermatology patients. J Am Acad Dermatol. 2017 Nov; 77 (5):980-981. doi: 10.1016/j.jaad.2017.06.035. PubMed PMID: 29029912.

Updyke K, Urso B, Beg S, Solomon J (October 09, 2017) Developing a Continuous Quality Improvement Assessment Using a Patient-Centered Approach in Optimizing Systemic Lupus Erythematosus Disease Control. Cureus 9(10): e1762. doi:10.7759/cureus.1762

Kailas A, Solomon JA, Rigel DS, Mostow E, McMichael AJ, Pritchett EN, Jackson-Richards D, Desai SR, Taylor SC The Importance of Recognition of the Skin Cancer Risk of Native Americans: A Call to Action. SKIN The Journal of Cutaneous Medicine, [S.l.], v. 1, n. 2, p. 107-108, aug. 2017. ISSN 2574-1624. Available at: <<http://jofskin.org/index.php/skin/article/view/24>>. Date accessed: 10 sep. 2017. doi:<https://doi.org/10.25251/skin.1.2.10>.

Kailas, Ajay; Solomon, James; Mostow, Elliot; Rigel, Darrel; Kittles, Rick; Taylor, Susan; Sadhwani, Divya; Choi, Hyunji; Schmitt, Amanda. Use of a modified Fitzpatrick scale in the understanding of skin cancer risk among people of color: 4946 2017 J Am Acad Dermatol 76 (6) AB276

Wu JJ, Egeberg A, Solomon JA, Osuntokun O, Goldblum O, Moriarty S, Zhao F, Korman N, Vincent M. Ixekizumab treatment shows a neutral impact on the glucose and lipid profile of patients with moderate-to-severe psoriasis: Results from UNCOVER-1,-2, and-3. J Inv Dermatol ESDR Meeting Abstract 396: 137 (10) S260-S260 Sep 2017

Urso, Brittany; Siddiqui, Fariha; Updyke, Katelyn M; Solomon, James. The study of basal cell carcinoma nevus syndrome through continuous quality improvement assessment—complex adaptive systems. J Am Acad Dermatol 2017, 76 (6) AB257

Urso, Brittany; Updyke, Katelyn; Solomon, James. Basal cell carcinoma nevus syndrome: Population of patients negative for chromosome 9 mutations: 5276 J Am Acad Dermatol 2017 76 (6) AB54

Nergard-Martin J, Siddiqui F, Kailas A, Winslow M, Solomon J A. Why Outcome Measures in Dermatology Are Becoming Patient Centric. Current Dermatology Reports 2017: 6 (3) 178–185 Online June 2017

Updyke KM, Urso B, Solomon JA, Brooks I, Burton V, Dellavalle RP. Identifying the most influential social media networks utilized by different populations of patients with autoimmune diseases. Oral poster presentation, 2017 Society for Investigative Dermatology Annual Meeting, Portland, OR. April 2017  
Updyke KM, Urso B, Solomon JA, Brooks I, Burton V, Dellavalle RP. An overview of social media posts related to psoriasis patients' perspectives towards Humira. Oral poster presentation, 2017 Society for Investigative Dermatology Annual Meeting, Portland, OR. April 2017

Urso B, Updyke KM, Solomon JA. The study of Basal Cell Carcinoma Nevus Syndrome through Continuous Quality Improvement Assessment- Complex Adaptive Systems. Oral poster presentation, 2017 Society for Investigative Dermatology Annual Meeting, Portland, OR. April 2017

Urso B, Updyke KM, Domozych R, Solomon JA, Brooks I, Burton V, Dellavalle RP. Acne treatment utilization among patients on social media platforms. Oral poster presentation, 2017 Society for Investigative Dermatology Annual Meeting, Portland, OR. April 2017

Updyke KM, Urso B, Solomon JA, Beg S. Identifying the role of molecular mimicry with exogenous nuclei antigens in affecting the exacerbations and remissions of systemic lupus erythematosus through patient centered outcome research methodology. Poster presentation, 75<sup>th</sup> Annual American Academy of Dermatology, Orlando, FL. March 2017.

Updyke KM, Urso B, Nergard J, Domozych R, Brooks I, Solomon JA. Utilization of a new IT platform promoted globally through social media to apply continuous quality assessments to deliver patient-centered care in those with autoimmune diseases. Poster presentation, 75<sup>th</sup> Annual American Academy of Dermatology, Orlando, FL. March 2017.

Urso B, Updyke KM, Solomon JA. Advanced basal cell carcinomas appear preferentially on the scalp of patients with Basal Cell Carcinoma Nevus Syndrome. Poster presentation, 75<sup>th</sup> Annual American Academy of Dermatology, Orlando, FL. March 2017.

Urso B, Updyke KM, Solomon JA. Basal Cell Carcinoma Nevus Syndrome: Population of patients negative for Chromosome 9 mutations. Poster presentation. Poster presentation, 75<sup>th</sup> Annual American Academy of Dermatology, Orlando, FL. March 2017.

Urso B, Updyke KM, Solomon JA. The study of Basal Cell Carcinoma Nevus Syndrome through Continuous Quality Improvement Assessment- Complex Adaptive Systems (abstract). *J Invest Dermatol.*;137(5):s23, 2017

Urso B, Updyke KM, Domozych R, Solomon JA, Brooks I, Burton V, Dellavalle R. Acne treatment utilization among patients on social media platforms (abstract). *J Invest Dermatol.*;137(5):s66, 2017

Updyke KM, Urso B, Solomon JA, Brooks I, Burton V, Dellavalle RP. Identifying the most influential social media networks utilized by different populations of patients with autoimmune diseases (abstract). *J Invest Dermatol.*;137(5):s13, 2017

Updyke KM, Urso B, Solomon JA, Brooks I, Burton V, Dellavalle RP. An overview of social media posts related to psoriasis patients' perspectives towards Humira (abstract). *J Invest Dermatol.*;137(5):s13, 2017

Urso B, Updyke KM, Solomon JA. Advanced basal cell carcinomas appear preferentially on the scalp of patients with Basal Cell Carcinoma Nevus Syndrome (abstract). *J Am Acad Dermatol*:76(6) S1 AB35, 2017

Updyke, Katelyn; Siddiqui, Fariha; Urso, Brittany; Domozych, Renee; Brooks, Ian; Solomon, James. Social media "listening" used to compare patient views on Enbrel to other treatments for psoriasis: *J Am Acad Dermatol* 2017, 76 (6) AB239

Urso B, Updyke KM, Solomon JA. Basal Cell Carcinoma Nevus Syndrome: Population of patients negative for Chromosome 9 mutations (abstract). *J Am Acad Dermatol*: 76 (6) S1, AB54. 2017

Updyke KM, Urso B, Solomon JA, Beg S. Identifying the role of molecular mimicry with exogenous nuclei antigens in affecting the exacerbations and remissions of systemic lupus erythematosus through patient centered outcome research methodology (abstract). Presented *J Am Acad Dermatol*. March 2017.

Updyke KM, Urso B, Nergard J, Domozych R, Brooks I, Solomon JA. Utilization of a new IT platform promoted globally through social media to apply continuous quality assessments to deliver patient-centered care in those with autoimmune diseases (abstract). Presented *J Am Acad Dermatol*. March 2017.

Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged  $\geq 65$  years with advanced basal cell carcinoma. *Oncotarget*. 2016 Nov 15;7(46):76118-76124. doi:10.18632/oncotarget.12660. PubMed PMID: 27764798; PubMed Central PMCID: PMC5342800.

Updyke, K., Urso, B., & Solomon, J. A. (2016). Developing a continuous quality improvement assessment using a patient-centered approach in optimizing SLE disease control. *Dermatology Online Journal*, 22(9). Retrieved from <https://escholarship.org/uc/item/0496s3p4>.

Tyring S, Solomon JA, Staedtler G, Lott JP, Nkulikiyinka R, Shakery K. Patient-Reported Outcomes of Azelaic Acid Foam 15% for Patients With Papulopustular Rosacea: Secondary Efficacy Results From a Randomized, Controlled, Double-blind, Phase 3 Trial *Cutis*. 2016 October;98(4):269-275

Solomon, JA. Clinical Trial Networks Across the US. International Federation of Dermatology Clinical Trials Networks Newsletter, 2016 Issue 12

Urso, B., Updyke, K., & Solomon, J. A. (2016). Basal Cell Carcinoma Nevus Syndrome: Population of patients negative for Chromosome 9 mutations. *Dermatology Online Journal*, 22(9). Retrieved from <https://escholarship.org/uc/item/4hs2264b>

Urso, B., Updyke, K., & Solomon, J. A. (2016). Advanced basal cell carcinomas appear preferentially on the scalp of patients with Basal Cell Carcinoma Nevus Syndrome. *Dermatology Online Journal*, 201622(9). Retrieved from <https://escholarship.org/uc/item/9sg5t9r0>

Updyke KM, Urso B, Solomon JA. Developing a continuous quality improvement assessment using a patient-centered approach in optimizing SLE disease control. Poster presentation, 7<sup>th</sup> International Dermato-Epidemiology Association Congress and Keratinocyte Carcinoma Consortium, Aurora, CO. September 2016

Updyke KM, Urso B, Solomon JA. Developing a continuous quality improvement assessment using a patient-centered approach in optimizing SLE disease control. Oral presentation, 7<sup>th</sup> International Dermato-Epidemiology Association Congress and Keratinocyte Carcinoma Consortium, Aurora, CO. September 2016

Urso B, Updyke KM, Solomon JA. Advanced basal cell carcinomas appear preferentially on the scalp of patients with Basal Cell Carcinoma Nevus Syndrome. Poster presentation, 7<sup>th</sup> International Dermato-Epidemiology Association Congress and Keratinocyte Carcinoma Consortium, Aurora, CO. September 2016

Urso B, Updyke KM, Solomon JA. Basal Cell Carcinoma Nevus Syndrome: Population of patients negative for Chromosome 9 mutations. Poster presentation, 7<sup>th</sup> International Dermato-Epidemiology Association Congress and Keratinocyte Carcinoma Consortium, Aurora, CO. September 2016

Solomon JA, Tyring S, Staedtler G, Sand M, Nkulikiyinka R, Shakery K. Investigator-Reported Efficacy of Azelaic Acid Foam 15% in Patients With Papulopustular Rosacea: Secondary Efficacy Outcomes From a Randomized, Controlled, Double-blind, Phase 3 Trial. *Cutis*. 2016 September; 98(3):187-194.

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. *N Engl J Med*. 2016 Jul 28; 375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. PubMed PMID: 27299809.

Kailas A, Solomon JA, Mostow EN, Rigel DS, Kittles R, Taylor SC. Gaps in the understanding and treatment of skin cancer in people of color. *J Am Acad Dermatol*. 2016 May;74 (5):1020-1.

Nergard J, Caldwell C, Stines M, Solomon JA, Results from a global survey of patient perspectives among females who developed melanoma in association with indoor tanning. *J Am Acad Dermatol* 72(5S1): AB175, 2015

Chang Anne, Arron Sarah, Migden Michael, Solomon James, Yoo Simon, Day Bann-Mo, McKenna Edward, Sekulic Aleksandar. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. *Orphanet Journal of Rare Diseases*.2016, 11:120. <http://www.ojrd.com/content/11/1/120>

Urso B, Updyke KM, Solomon JA, Iarrabino A, Stines M, Doctor M, Domozych R. Chromosome 9 mutations absent in some patients with Basal Cell Carcinoma Nevus Syndrome. Poster presentation, University of Central Florida College of Medicine FIRE Conference, Orlando, FL. March 17, 2016.

Updyke KM, Urso B, Solomon JA, Beg S. Developing a continuous quality improvement assessment using a patient-centered approach in optimizing SLE disease control. Poster presentation, University of Central Florida College of Medicine FIRE Conference, Orlando, FL. March 17, 2016.

Nergard, J., Caldwell, C., Barr, M., Dellavalle, R. P, & Solomon, J. A. (2016). Perceptions of indoor vs. outdoor tanning risks among melanoma patients who have a history of indoor UV tanning: an international internet survey. *Dermatology Online Journal*, 22(9). Retrieved from <https://escholarship.org/uc/item/9n08s09s>

Siddiqui FT, Solomon JA, Burden of pediatric basal cell carcinoma nevus syndrome on the patients and families from the perspectives of parents and guardians. *Journal Of Investigative Medicine* **Volume:** 64 **Issue:** 3 **Meeting Abstract:** P3 **Published:** Mar 2016

Urso B, Updyke KM, Solomon JA, Iarrabino A, Stines M, Doctor M, Domozych R. Chromosome 9 mutations absent in some patients with Basal Cell Carcinoma Nevus Syndrome. Poster presentation, Orlando Dermatology & Aesthetics Conference, Championsgate, FL. January 15, 2016.

Updyke KM, Urso B, Solomon JA, Iarrabino A, Stines M, Domozych R. Identifying the role of molecular mimicry with exogenous nucleic antigens in affecting the exacerbations and remissions of systemic lupus erythematosus through patient centered outcome research methodology. Poster presentation, Orlando Dermatology & Aesthetics Conference, Championsgate, FL. January 15, 2016.

Domozych R , Solomon JA, and Stines M. Malignant Melanoma: Incidence Including Sex, Body Location, And Age Distribution Among Over 500,000 Patients Seen In A Nationwide Dermatology Group Practice. Presented 73<sup>rd</sup> Annual Meeting of American Academy Dermatology. San Francisco CA March 2015.

Nergard J, Caldwell C, Stines M, Solomon JA, Results from a global survey of patient perspectives among females who developed melanoma in association with indoor tanning. Presented 73<sup>rd</sup> Annual Meeting of American Academy Dermatology. San Francisco CA March 2015.

Domozych R , Solomon JA, and Stines M. Malignant Melanoma: Incidence Including Sex, Body Location, And Age Distribution Among Over 500,000 Patients Seen In A Nationwide Dermatology Group Practice. Presented 41<sup>st</sup> Annual Eastern-Atlantic Student Research Forum, Miami FL Feb 2015.

Domozych R , Solomon JA, and Stines M. Malignant Melanoma: Incidence Including Sex, Body Location, And Age Distribution Among Over 500,000 Patients Seen In A Nationwide Dermatology Group Practice. *J Am Acad Dermatol* 72(5S1) AB99, 2015

Sekulic A, Migden MR, Lewis K, Hainsworth JD, **Solomon JA**, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A, ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. *J Am Acad Dermatol*. 72(6):1021-1026, 2015

Nergard J, Caldwell C, Stines M, Solomon JA, Results from a global survey of patient perspectives among females who developed melanoma in association with indoor tanning. Presented 41<sup>st</sup> Annual Eastern-Atlantic Student Research Forum, Miami FL Feb 2015.

Glener J, Solomon JA, Dellavalle R, Armstrong A. Determination Of Whether The Increase In Biopsy Rate Among Dermatologists As Reported By The Us Government Accounting Office (Gao) Is Associated With An Increasing Rate Of Biopsies With Normal Pathology. Presented 41<sup>st</sup> Annual Eastern-Atlantic Student Research Forum, Miami FL Feb 2015.

Solomon JA, Schuering BS. An Update on the IDEOM (International Dermatology Outcome Measures) Initiative to Restructure Current Psoriasis Outcome Assessment Measures to a Globally Uniform Set of Patient-Centric Outcome Measures for Use in Clinical Trials and Clinical Practice. *Psoriasis Forum* 21(1); 50-52, 2015.

Solomon JA, Ramshaw B, Lewis S, Stines M, Domozych R, Iarrobino A, Caldwell C, Bég S, Brooks IS. Complex Adaptive Systems Approach: Clinical Quality Improvement Assessments Applied to Dermatology. Part II- Applied to Systemic Lupus Erythematosus. *Practical Dermatol*. 12(10): 39-48, 2015.

Solomon, JA. Development of Uniform Protocol for Alopecia Areata Clinical Trials. *J Investig Dermatol Symp Proc* 17: 63-66; doi:10.1038/jidsymp.2015.45

Nergard J, Caldwell C, Stines M, Solomon JA, Results from a global survey of patient perspectives among females who developed melanoma in association with indoor tanning. *J Am Acad Dermatol* 72(5S1): AB175, 2015

Chang ALS, Arron AT, Migden MR, Solomon JA, Yoo S, Day B-M, McKenna E, Sekulic A. Safety and Efficacy of Vismodegib in Patients With Basal Cell Carcinoma Nevus Syndrome: Analysis of the ERIVANCE BCC and Expanded Access Studies. Presented at Fall Dermatology Conference Los Vegas NV, October 2014.

Solomon JA, Alam M, Dellavalle R, Glener J, Lewis S, Nodzenski M, Duke J, Stines M, Poon E, Armstrong A, Oswald M. Skin biopsy frequency and results over an 8-year period within a large US dermatology group practice. Presented American Society Dermatological Surgery 2015 Annual Meeting, Chicago IL October 2014

Iarrobino A, Domozych R, Urso B, Stines M, Solomon JA. Application of Complex Adaptive Systems Research Methodology to Basal Cell Nevus Syndrome: Preliminary Findings. Oral presentation, BCCNS Conference, Orlando, FL. September 20, 2014.

Caldwell, Chauncey; Solomon, James A; Lewis, Suzie. The Prevalence of Alopecia Areata Among 572,617 Pediatric Patients Seen in Dermatology Private Practices throughout the United States. *Pediatric Dermatology* 2014, 31 (5) 645

Caldwell CC, Solomon J, Lewis, Suzie. The Prevalence of Pediatric Alopecia Areata among 572,617 Patients Seen in Dermatology Private Practices throughout Florida and Ohio. Poster presentation Society of Pediatric Dermatology. Couer D' Alene, ID. July 9-12, 2014.

Sekulic, Aleksandar; Schadendorf, Dirk; Solomon, James; Hainsworth, John; Lewis, Karl; Dirix, Luc; Migden, Michael. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. *J Am Acad Dermatol* 2014, 70 (5) AB137

O'Neill JL, Shetty B, Sun Lee Y, Solomon JA, Patel N, Davis SA, Taheri A, Huang KE, Landis ET, Robins DN, Williford PM, Feldman SR, Pearce DJ. Comparing demographic characteristics and adverse event rates at two dermatologic surgery practices. *J Cutan Med Surg* 18(5) 337-40, 2014

Boehncke W-H, Martinez DA, Solomon JA, and Gottlieb AB. Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review. *J. Rheumatol* 41:2301–5, 2014

Lewis K, Sekulic A, Hauschild A, Migden MR, Oro AE, LoRusso P, Rudin CM, Dirix L, Solomon JA, Hainsworth JD, Williams S, Hou J, Von Hoff DD. Vismodegib in the Treatment of Patients With Metastatic Basal Cell Carcinoma and Distant Metastases: Survival in the Pivotal Phase 2 and Phase 1 Studies. Presented at the 50th Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2014; Chicago, Illinois, USA.

Lewis S, Solomon J, Stines M, Ramshaw Bég S. Designing a Continuous Quality Improvement Assessment System Utilizing Complex Adaptive Systems Science to Improve Treatment Outcomes in Patients with SLE. FL Med Soc Mtg. Orlando FL June 2014

Stines M, Solomon JA, Ramshaw B, Kolpashchikov DM, Lewis S, Domozych R, Bég S. Identifying the Role of Molecular Mimicry in SLE immune complex disease. FL Med Soc Mtg Orlando FL June 2014

Schadendorf D, Migden MR, Oro AE, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Hou J, Lyons B, Sekulic A. Vismodegib in Advanced Basal Cell Carcinoma: 24-Month ERIVANCE Update. Presented at the 10th annual European Association of Dermato-Oncology (EADO) Congress; May 7-10, 2014; Vilnius, Lithuania.

Solomon J, Ramshaw B, Lewis S, Stines M, Domozych R. Theoretical Basis for Molecular Mimicry & Cross Reactivity as Explanation of Spontaneous Exacerbations of Systemic Lupus Erythematosus. 9<sup>th</sup> Int Congress Autoimmunity, Nice, France April 2014

Stines M, Solomon JA, Ramshaw B, Kolpashchikov DM, Lewis S, Domozych R, Bég S. Identifying the Role of Molecular Mimicry in SLE immune complex disease. Translational Science 2014 Annual Meeting, Washington DC April 2014

Lewis S, Solomon J, Stines M, Ramshaw Bég S. Designing a Continuous Quality Improvement Assessment System Utilizing Complex Adaptive Systems Science to Improve Treatment Outcomes in Patients with SLE. Am Fed Med Research Eastern Reg Mtg. Washington, DC April, 2014

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Hou J, Lyons B, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study. American Academy of Dermatology - 72nd Annual Meeting, 2014.

Chang ALS, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day B, Chen DM, Weiss GJ. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. *J Am Acad Dermatol.*70, 60-9, 2014.

Sekulic A, Migden MR, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Schadendorf D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. *AAD*, March 2014

Lewis S, Solomon J, Stines M, Ramshaw Bég S. Designing a Continuous Quality Improvement Assessment System Utilizing Complex Adaptive Systems Science to Improve Treatment Outcomes in Patients with SLE. *J Invest Medicine* 62 (4) 776, 2014

O'Neill JL, Taheri A, Solomon JA, Pearce DJ. Postoperative hemorrhage risk after outpatient dermatologic surgery procedures. *Dermatol Surg.* 2014 Jan; 40(1):74-6. doi: 10.1111/dsu.12357. Epub 2013 Nov 14. PubMed PMID: 24237907.

Solomon JA, Ramshaw B, Stines M, Lewis S, Domozych R, Iarrobino A, Caldwell C, Bég SA. Complex Adaptive Systems Approach to Continuous Quality Improvement Assessments Applied to Dermatology, Part I (Overview) *Practical Dermatology*, 1:38-9, 2014

Caldwell C, Solomon J, Chever D. The Prevalence of Alopecia Areata among 572,617 Patients Seen in Dermatology Private Practices throughout the US. Poster presentation Mauderm Meeting, Wailea, HI. January 26-30, 2014.

Sekulic A, Weiss GJ, Solomon JA, Rudin CM, Guillot B. Amenorrhea or Irregular Menses in Patients Treated With Vismodegib. Presented at: 2014 Winter Clinical Dermatology Conference Hawaii®; January 17-22, 2014; Kohala Coast, Hawaii.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Lyons B, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 24-Month Update of the Pivotal ERIVANCE BCC Study. Presented at the 10th International Meeting of the Society for Melanoma Research; November 17-20, 2013; Philadelphia, Pennsylvania, USA.

Dirix L, Sekulic A, Migden MR, Oro AE, Lewis K, Hainsworth JD, Solomon JA, Hou J, Lyons B, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 24-Month Update of the Pivotal ERIVANCE BCC Study. *European Academy of Dermatology and Venereology - 22nd Congress*, 2013.

Sekulic, A; Migden, MR; Oro, AE; Dirix, L; Lewis, K; Hainsworth, JD; Solomon, JA; Hou, J; Lyons, B; Schadendorf, D. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 24-month update of the pivotal ERIVANCE BCC study. *Pigment Cell & Melanoma Research.* 2013, 26 (6) 999

Solomon JA, Chever D, Caldwell C. The prevalence of alopecia areata among 915,429 dermatology patients seen in dermatology private practice offices throughout the United States. *J Inv Dermatol* 133: S96, 2013.

Solomon JA, Chever D, Iarrobino A., Caldwell C. Successful control of adverse events associated with vismodegib treatment of advanced basal cell carcinoma by recognition of hedgehog pathway activity in normal adult tissue. *J Inv Dermatol* 133: S185, 2013.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Hou J, Lyons B, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients with Advanced Basal Cell Carcinoma (aBCC): 24-Month Update of the Pivotal ERIVANCE BCC Study. Presented at Society Melanoma Research Congress, Philadelphia 2013.

Dirix L, Sekulic A, Migden MR, Oro AE, Lewis K, Hainsworth JD, Solomon JA, Hou J, Lyons B, Schadendorf D. Long-Term Safety and Efficacy of Vismodegib in Patients with Advanced Basal Cell Carcinoma (aBCC): 24-Month Update of the Pivotal ERIVANCE BCC Study. Presented at European Acad Dermatol Venerol, Istanbul 2013

Sekulic, A. Hauschild, A. Migden, M. R. Oro, A. E. Lo Russo, P. Rudin, C. M. Lewis, K. Dirix, L. Solomon, J. A. Hainsworth, J. D. Yue, H. Hou, J. Von Hoff, D. D. Survival of patients with metastatic basal cell carcinoma and distant metastasis: the effect of vismodegib, a Hedgehog pathway inhibitor. *J Der Deutschen Dermatologischen Gesellschaft* 11:SI 7, 108, 2013

O'Neill, J. L. Lee, Y. S. Solomon, J. A. Patel, N. Shutty, B. Davis, S. A. Robins, D. N. Williford, P. M. Feldman, S. R. Pearce, D. J. Quantifying and Characterizing Adverse Events in Dermatologic Surgery. *Dermatol Surgery* 39 (6): 872-8, 2013

Sekulic A, Hauschild A, Migden MR, Oro AE, Lo Rosso PL, Rudin CM, Lewis K, Dirix L, Solomon JA, Hainsworth JD, You H, McCusker M, Hou J, Von Hoff DD. Survival of patients with metastatic basal cell carcinoma and distant metastasis: the effect of vismodegib, a Hedgehog pathway inhibitor. *World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers - 7th.* 2013;11(s7):108.

Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M; U0267-301 & 302 Study Investigators. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. *Am J Clin Dermatol.* 2012 Aug 1;13(4):261-71. doi: 10.2165/11630710-000000000-00000. Erratum in: *Am J Clin Dermatol.* 2012 Dec 1;13(6):422. PubMed PMID: 22587791.

Sekulic A, Migden MR, Oro AE, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Dirix L, Hou J, Yue H, Hauschild A. Efficacy and safety of vismodegib in patients with advanced basal cell carcinoma (BCC): 12-month update of the ERIVANCE BCC study, *Ann Oncol* 23: S9, 361-375, 2012

Solomon JA, Oro A, Chang LS, Hainsworth J, Goldberg L, Hamid O, LoRusso P, Friedlander P, Olencki T, Sekulic A, Miller C, Day B, Chen D, Weiss GJ. Expanded access study of advanced basal cell carcinoma (aBCC) patients treated with the hedgehog pathway inhibitor vismodegib: Final analysis. Presented 2012 Fall Clinical Dermatology Conference, Las Vegas, NV, October 2012.

Solomon JA, Shutty B, Iarrobino A, Ramshaw B. Application of Complex Adaptive Systems Research Methodology to Elucidate New Treatment Approaches for locally advanced and metastatic cutaneous Squamous Cell Carcinoma, Part II. *Cutaneous Oncology Today*, October 2012.

Sekulic, A; Migden, MR; Oro, AE; Lewis, K; Hainsworth, JD; Solomon, JA; Yoo, S; Arron, ST; Friedlander, PA; Marmur, E. Efficacy and safety of vismodegib in patients with advanced basal cell carcinoma (bcc): 12-month update of the Erivance Bcc study. *Pigment Cell & Melanoma Research*. 2012, 25 (6) 886

Oro AE, Chang ALS, Solomon JA, Chen DM, Feng S, Weiss G. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor vismodegib: Interim analysis – locally advanced basal cell carcinoma cohort. Presented American Acad Dermatology Summer Meeting, Boston MA, August 2012.

Solomon JA, Shutty B, Iarrobino A, Ramshaw B. Application of Complex Adaptive Systems Research Methodology to Elucidate New Treatment Approaches for locally advanced and metastatic cutaneous Squamous Cell Carcinoma, Part I. *Cutaneous Oncology Today*, August 2012.

Solomon JA, Iarrobino A, Shutty B. Calcium Dependence of the SHH Pathway and Theoretical Implications in Oral Treatment of Locally Advanced and Metastatic Basal Cell Carcinomas. *Cutaneous Oncology Today* 1:9-13, 2012.

Sekulic A, Oro AE, Solomon JA, Hainsworth JD, Lewis K, Dirix L, Migden MR. A pivotal multicenter trial evaluation efficacy and safety of the hedgehog pathway inhibitor vismodegib (GCD-0449) in patients with advanced basal cell carcinoma. *J Am Acad Dermatol* 66S(4): AB149, 2012.

Murrell DF, Migden MR, Oro AE, Lewis K, Solomon JA, Yoo S, Mackey H, Caro I, Sekulic A. ERIVANCE BCC: A pivotal trial of the hedgehog pathway inhibitor vismodegib in locally advanced or metastatic basal cell carcinoma. *Australasian J Dermatol*, 53: S1,8, 2012.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. *New Engl J Med* 366: 2171-9, 2012.

Weiss, G. J. Oro, A. Chang, A. L. S. Solomon, J. A. LoRusso, P. M. Hamid, O. Chen, D. M. McKenna, E. Feng, S. Hainsworth, J. D. Expanded Access Study of Advanced BCC Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib. *Annals Oncol* 23 (S9): 362, 2012.

Murrell DF, Migden MR, Oro AE, Hauschild A, Lewis K, Solomon JA, Yoo S, Mackey H, Caro I, Sekulic A. A pivotal trial of the hedgehog pathway inhibitor vismodegib in locally advanced or metastatic basal cell carcinoma. Oral Presentation Austral College Dermatol Annual Meeting 2012.

Migden MR, Oro AE, Hauschild A, Lewis K, Solomon JA, Yoo S, Mackey H, Caro I, Sekulic A. Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Basal Cell Carcinoma: A Pivotal Multicenter Trial. Present at American Society Dermatological Surgery Annual Meeting, Chicago, November 2011

Sekulic, A; Migden, MR; Oro, AE; Dirix, L; Lewis, K; Hainsworth, JD; Solomon, JA; Yoo, S; Arron, ST; Friedlander, PA. CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC). *Melanoma Research*. 2011, 21 e9

Sekulic A, Migden MR, Oro AE, Luc Dirix, Karl Lewis, John D. Hainsworth, James A. Solomon, Simon Yoo, Sarah T. Arron, Philip A. Friedlander, Ellen Marmur, Charles M. Rudin, Anne L.S. Chang, Jennifer A. Low, A. Barbara Mueller, Robert L. Yauch, Josina C. Reddy, and Axel Hauschild. A pivotal multicenter trial of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Presented at the European Association for Dermatology and Venereology (EADV) Meeting Lisbon, Portugal: Saturday 22 October 2011.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rubid CM, Chang ALS, Low JA, Mueller B, Yauch RL, Reddy JC, Hauschild A. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC). Presented at European Association for Dermato-Oncology (EADO) Meeting Nantes, France: 21 June 2011.

O'Neill, JL, Lee YS, Solomon JA, Patel N, Shetty B, Robins DN, Williford PM, Feldman SR, Pearce DJ. Quantifying and characterizing adverse events in dermatologic surgery. Poster presented at the Society of Investigative Dermatology 71st Annual Meeting, Phoenix, AZ, 4-7 May 2011.

O'Neill J, Pearce DJ, Lee Y, Solomon JA, Williford P, Robins DN, Feldman SR. Quantifying and characterizing adverse events in dermatologic surgery. *J Inv Dermatol*. 131 (S1): S42, 2011.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Caro I, Mackey HM, Yauch RL, Reddy JC, Axel Hauschild A. A pivotal multicenter trial evaluating efficacy and safety of the hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. e-poster. Presented at Am Acad Dermatol Annual Meeting, 2011

O'Neill J, Pearce D, Solomon J, Williford P, Feldman S. Quantifying and characterizing adverse events in dermatological surgery. *J Am Acad Dermatol* 64(S1) AB169, 2011.

Solomon, J.A. Galen Disease, Delusions of Grandeur in an Authoritative Clinical Investigator *Arch Dermatol*, 147(6): 723, 2011

Herzog, J.L., Solomon, J.A., Draelos, Z., Fleischer Jr, A., Stough, D., Wolff, D.I., Abramovitz, W., Werschler W., Wilson, D., Green E., Duffy, M., Rothaul, A., Tansley R. Randomized, Double-Blind, Vehicle-Controlled Crossover Study To Determine the Anti-Pruritic Efficacy, Safety and Local Dermal Tolerant of a Topical Formulation (SRD174 Cream) of the Long-Acting Opioid Antagonist Nalmefene in Subjects with Atopic Dermatitis. *J Drugs Dermatol*. 10(8):853-860, 2011.

Giffune, J., and Solomon, J.A.: Dietary Management for Systemic Dermatitis from Ingestion of Nickel, Chrome, and Cobalt. Presented at American Contact Dermatitis Society Meeting, December, 1993

Solomon, J.A., Harrist, T. J., and Maroney, M.: Reversal of Treatment Resistant Alopecia Areata by Withdrawal of Systemic Antigens: Summary of 26 Patients. Presented at AAD Summer Session, Toronto, July 1993.

Solomon, J.A., Harrist, T. and Maroney, M.: Reversal of Alopecia Universalis by Withdrawal of Systemic Exposures to Ingested Antigens: Summary of 4 Patients. *Pediatric Dermatology* 9:2:230, 1992.

Solomon, J.A., and Maroney, M.J.: Psoriasisiform Systemic Contact Dermatitis; Association of Antigenicity with Acquired Metabolic Deficiencies. Presented at Annual Meeting of American Contact Dermatitis Society, Dallas, December, 1991.

Solomon, J.A., and Pochi, P.E.: Acne Vulgaris. In: *Dermatologic Immunology and Allergy*, pp. 649 - 660, 1985, ed. J. Stone. St. Louis, C.V. Mosby Co.

Solomon, J.A., and Baratz, R.S.: Systemic Dermatitis and Dental Metal Antigens. Presented at Eastern Region Meeting of Society for Investigative Dermatology, October, 1984.

Baratz, R.S., and Solomon, J.A.: Galvanic Release of Antigenic Metals from Dental Sources. *Clinical Research* 32:570A, 1984.

Solomon, J.A., and Baratz, R.S.: Systemic Dermatitis with Hypersensitivity to Metals from Dental Sources—Types of Eruptions. *Clinical Research* 32:616A, 1984.

Solomon, J.A., and Baratz, R.S.: Systemic Reactions which Improved Following Removal of Dental Metal Antigens Preliminary Findings. Presented at American Federation for Clinical Research Annual Meetings 1984. *Clinical Research* 32:146A, 1984.

Solomon, J.A.: Assay Process for Determining Mitogen or Antigenic Response. United States Patent Office, New Patent Application, pp. 14, 1983.

Fiumara, N.J., and Solomon, J.A.: Recurrent Herpes Simplex Virus Infection and Erythema Multiforme: A report of three patients. *Sexually Transmitted Diseases* 10:144—147, 1983.

Wax, F.D., and Solomon, J.A.: Fluorescent Dye for Marking Patch Test Sites. *Archives of Dermatology* 118:449, 1982.

Chou, I., Zeiger, J., Solomon, J.A., and Black, P.H.: Stimulation of Plasminogen Activator Expression and Induction of DNA Synthesis by Microtubule-Disruptive Drugs. *Biochemical and Biophysical Research Communications* 101:1266:1273, 1981.

Klein, E., Hahn, G., R • W., Solomon, J.A., Schwartz, R.A., Boone, C.Q., Austin, F.C., Klein, L., Djerassi, I., Cavins, J.A., Milgrom, H., and Holtermann, O.A.: Immunotherapy of Skin Cancer and Other Neoplasms Involving the Skin. In: *Immunodermatology* eds. B. Safai, and R. A. Good. New York Plenum Medical Book Co., pp. 633-643, 1981.

Solomon, J.A., Chou, I., Schroder, E.W., and Black, P.H.: Evidence for Membrane Association of Plasminogen Activator Activity in Mouse Macrophages. *Biochemical and Biophysical Research Communications* 94:480—485, 1980.

Klein, E., Schwartz, R.A., Case, R.W., Holtermann, O.A., Solomon, J., Hahn, G.M., Boone, C.W., and Djerassi, I.: Accessible Tumors. In: *Clinical Immunotherapy* ed. A.F. LoBuglio, New York, Marcel Dekker Inc., pp. 31-71, 1980.

Schwartz RA, Vickerman CE, Phelan JT, Burgess GH Klein, E., Solomon, J., O'Loughlin, S., Southwick, G.J., Baitman, L., and Laor, Y.: Mutilating Sclerosing Basal Cell Epithelioma. *Journal of Surgical Oncology* 12:131—135, 1979.

Klein, E., Hahn, G.M., Solomon, J.A., Kim, U., Schwartz, R.N., Case, R.W., Herman, H., Milgrom, H., and Holtermann, O.A.: Explorations of Antimitotic Agents in the Treatment of a Congenital Disease. Ichthyosis Linearis Circumflexa. *Journal of Surgical Oncology* 11:85—88, 1979.

Klein, E., Boone, C.W., Holtermann, O., Case, R.W., Solomon, J., and Djerassi, I.: Immunological Approach to Management of Cancer. *Pontifical Academy of Science Meetings*, 1977.

Solomon, J.A.: Cytochemical Studies on Thymus Independent Lymphocytes. *Dissertation Abstracts International* 37:2765-B, 1976.

Solomon JA. Cytochemical Studies of Thymus Dependent and Independent Lymphocytes. *Anatomical Record* 184 (3), 537, 1976.